Trials / Completed
CompletedNCT05498467
The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis
The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis: A Randomized Controlled Trial With Anakinra vs. Placebo
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Herlev and Gentofte Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The study will investigate if Anakinra can ameliorate allergic contact dermatitis in participants with known nickel allergy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anakinra | 100 mg Anakinra injections s.c. |
| DRUG | Sodium Chloride 9mg/ml Injection | 9 mg Sodium Chloride injections s.c. |
Timeline
- Start date
- 2022-10-11
- Primary completion
- 2023-12-01
- Completion
- 2024-08-01
- First posted
- 2022-08-12
- Last updated
- 2025-05-20
- Results posted
- 2025-05-20
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT05498467. Inclusion in this directory is not an endorsement.